Trastuzumab Recruiting Phase 2 Trials for Neoplasms / Tumors, Solid / Bladder Cancers / Salivary Cancer / Biliary Cancer Treatment

Indications	Status	Purpose	Phase
DBCOND0027948 (Neoplasms) DBCOND0074335 (Tumors, Solid) DBCOND0050427 (Bladder Cancers) DBCOND0080787 (Salivary Cancer) DBCOND0038607 (Biliary Cancer)	Recruiting	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT02091141	My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors	Erlotinib (DB00530) Vemurafenib (DB08881) Alectinib (DB11363) Vismodegib (DB08828) Trastuzumab (DB00072) Pertuzumab (DB06366) Atezolizumab (DB11595) Cobimetinib (DB05239)